Dupixent Cancer Risk: What Patients Should Know

Dupixent is an IL-4/IL-13 inhibitor prescribed for eczema, asthma, nasal polyps, COPD, and other inflammatory conditions. Current monitoring is evaluating whether immune-pathway suppression may be associated with higher malignancy risk in some patients.

Reported diagnoses under review include lymphoma, skin cancers, and solid tumors. Each situation depends on exposure history, diagnosis timing, and medical evidence.

If you used Dupixent and were later diagnosed with cancer, preserving treatment records and pathology reports is a critical first step for legal review.